334970 — Prestige Biologics Co Income Statement
0.000.00%
- KR₩251bn
- KR₩384bn
- KR₩2bn
Annual income statement for Prestige Biologics Co, fiscal year end - June 30th, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 6 M |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 185 | 0 | 3,227 | 15.6 | 1,730 |
Cost of Revenue | |||||
Gross Profit | 185 | 0 | 2,354 | 3.6 | 518 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 12,646 | 22,601 | 30,064 | 37,293 | 23,836 |
Operating Profit | -12,462 | -22,601 | -26,837 | -37,277 | -22,105 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -22,057 | -31,033 | -39,378 | -49,718 | -17,980 |
Provision for Income Taxes | |||||
Net Income After Taxes | -22,057 | -31,033 | -39,378 | -49,718 | -17,980 |
Net Income Before Extraordinary Items | |||||
Net Income | -22,057 | -31,033 | -39,378 | -49,718 | -17,980 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -22,057 | -31,033 | -39,378 | -49,718 | -17,980 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -694 | -875 | -886 | -950 | -294 |
Dividends per Share |